Ankündigung • Oct 26
Nabriva Therapeutics plc Files Form 15 Nabriva Therapeutics plc has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Ordinary Shares under the Securities Exchange Act of 1934, as amended. The par value of the company's Ordinary Shares, nominal value $0.01 per share. Ankündigung • Sep 08
Nasdaq to Delist the Ordinary Shares of Nabriva Therapeutics On September 7, 2023, The Nasdaq Stock Market announced that it will delist the ordinary shares of Nabriva Therapeutics plc. Nabriva Therapeutics plc’s securities were suspended on August 1, 2023, and have not traded on Nasdaq since that time. Ankündigung • Jul 25
Nabriva Therapeutics Receives A Delisting Determination Letter from Nasdaq On July 21, 2023, Nabriva Therapeutics plc (the Company") received a delisting determination letter (the Determination Letter") from The Nasdaq Stock Market LLC (Nasdaq"). The Determination Letter indicated that, based on (i) the Company's continued non-compliance with the Nasdaq Capital Market's requirement to have a minimum stockholders' equity of $2,500,000 under Nasdaq Listing Rule 5550(b)(1) (the Rule") and (ii) the Company's confirmation that it did not intend to submit a plan to regain compliance with the Rule, the Company's ordinary shares, nominal value $0.01 per share (the Ordinary Shares"), will be suspended from trading on Nasdaq at the open of business on August 1, 2023, unless the Company requests an appeal of this determination. The Determination Letter also indicated that unless the Company requests an appeal of Nasdaq's determination, Nasdaq intends to file a Form 25-NSE with the Securities and Exchange Commission in order to effect the formal delisting of the Company's Ordinary Shares from Nasdaq. The Company does not plan to appeal Nasdaq's determination. As previously disclosed, the Company was initially notified by Nasdaq on May 25, 2023 that the Company was not in compliance with the Rule because the stockholders' equity (deficit) of the Company of $(4,357,000) as of March 31, 2023, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, was below the minimum stockholders' equity requirement of $2,500,000. The Ordinary Shares may be eligible to be quoted on the Pink Open Market operated by the OTC Markets Group Inc. if a market maker sponsors the security and complies with Rule 15c2-11 under the Securities Exchange Act of 1934, as amended, but the Company can provide no assurances that a public market for trading the Ordinary Shares will exist after the expected suspension of trading on August 1, 2023. Ankündigung • May 16
Nabriva Therapeutics plc announced delayed 10-Q filing On 05/15/2023, Nabriva Therapeutics plc announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Ankündigung • Jan 21
Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer On January 15, 2023, in connection with the separation of employment of Mr. Schroeder, the Board of Directors appointed J. Christopher Naftzger as Interim Chief Executive Officer, effective immediately. J. Christopher Naftzger, age 56, has served as the Company’s general counsel and secretary since September 1, 2021. Previously, Mr. Naftzger served as General Counsel and Corporate Secretary of Krystal Biotech, an emerging-stage, gene therapy company, from February 2020 to May 2021. Before joining Krystal, he was Vice President, Deputy General Counsel and Assistant Secretary of Nabriva Therapeutics from January 2017 to January 2020. Prior to Nabriva, Mr. Naftzger served as Vice President, General Counsel, Chief Compliance Officer, and Secretary of Unilife Medical Solutions, a developer and manufacturer of innovative drug delivery systems. Mr. Naftzger also held senior in-house counsel positions with Chesapeake Corporation and Koch Industries, and was a corporate partner with Blank Rome LLP in Washington, DC. Mr. Naftzger obtained his undergraduate degree from Hampden-Sydney College and his law degree from the Willamette University College of Law. Major Estimate Revision • May 12
Consensus revenue estimates fall by 10% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$43.9m to US$39.3m. Forecast losses increased from -US$0.67 to -US$0.73 per share. Pharmaceuticals industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$2.00 unchanged from last update. Share price fell 28% to US$0.21 over the past week. Reported Earnings • May 06
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: US$0.20 loss per share (up from US$0.53 loss in 1Q 2021). Revenue: US$8.02m (up 217% from 1Q 2021). Net loss: US$11.8m (loss narrowed 16% from 1Q 2021). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 5.3%. Over the next year, revenue is forecast to grow 48%, compared to a 7.6% growth forecast for the industry in the US. Breakeven Date Change • Apr 27
No longer forecast to breakeven The 2 analysts covering Nabriva Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$15.0m in 2024. New consensus forecast suggests the company will make a loss of US$560.0k in 2024. Major Estimate Revision • Apr 05
Consensus revenue estimates fall by 17% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$52.8m to US$43.9m. Forecast losses increased from -US$0.62 to -US$0.67 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$4.00 to US$2.00. Share price fell 11% to US$0.42 over the past week. Breakeven Date Change • Mar 31
No longer forecast to breakeven The 2 analysts covering Nabriva Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$15.0m in 2024. New consensus forecast suggests the company will make a loss of US$560.0k in 2024. Breakeven Date Change • Jan 02
Forecast to breakeven in 2024 The 3 analysts covering Nabriva Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$10.6m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule. Recent Insider Transactions • Jan 01
CEO & Director recently bought US$57k worth of stock On the 28th of December, Theodore Schroeder bought around 100k shares on-market at roughly US$0.57 per share. This was the largest purchase by an insider in the last 3 months. Theodore has been a buyer over the last 12 months, purchasing a net total of US$114k worth in shares. Reported Earnings • Nov 12
Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.90 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$8.86m (up US$7.57m from 3Q 2020). Net loss: US$10.7m (loss narrowed 18% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Sep 17
CEO & Director recently bought US$57k worth of stock On the 14th of September, Theodore Schroeder bought around 50k shares on-market at roughly US$1.13 per share. This was the largest purchase by an insider in the last 3 months. This was Theodore's only on-market trade for the last 12 months. Major Estimate Revision • Aug 12
Consensus revenue estimates increase to US$29.6m The consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$25.2m to US$29.6m. Forecast losses expected to reduce from -US$1.29 to -US$1.11 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$3.68 to US$2.68. Share price fell 7.4% to US$1.12 over the past week. Reported Earnings • Aug 09
Second quarter 2021 earnings released: US$0.29 loss per share (vs US$1.37 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$8.24m (up US$7.76m from 2Q 2020). Net loss: US$11.8m (loss narrowed 24% from 2Q 2020). Executive Departure • Aug 04
Independent Director George Talbot has left the company On the 28th of July, George Talbot's tenure as Independent Director ended after 4.1 years in the role. As of March 2021, George still personally held only 4.76k shares (US$7.9k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 3.08 years. Board Change • Aug 04
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Stephen Webster was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Breakeven Date Change • Jul 13
No longer forecast to breakeven The 4 analysts covering Nabriva Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$16.5m in 2023. New consensus forecast suggests the company will make a loss of US$4.63m in 2023. Major Estimate Revision • May 27
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$29.9m to US$29.3m. 2021 losses expected to reduce from -US$1.67 to -US$1.48 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$6.00 unchanged from last update. Share price rose 2.7% to US$1.51 over the past week. Major Estimate Revision • May 13
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$30.8m to US$29.9m. 2021 losses expected to reduce from -US$1.95 to -US$1.67 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$6.00 unchanged from last update. Share price fell 14% to US$1.37 over the past week. Reported Earnings • May 09
First quarter 2021 earnings released: US$0.53 loss per share (vs US$2.46 loss in 1Q 2020) The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$2.53m (up 221% from 1Q 2020). Net loss: US$14.0m (loss narrowed 40% from 1Q 2020). Major Estimate Revision • Apr 17
Consensus revenue estimates increase to US$30.8m The consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$22.9m to US$30.8m. Forecast losses expected to reduce from -US$2.03 to -US$1.95 per share. Pharmaceuticals industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$6.00 unchanged from last update. Share price fell 9.6% to US$1.50 over the past week. Major Estimate Revision • Mar 18
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$15.3m to US$22.9m. EPS estimate unchanged from -US$2.03 at last update. Pharmaceuticals industry in the US expected to see average net income growth of 11% next year. Consensus price target down from US$9.00 to US$6.00. Share price rose 17% to US$2.05 over the past week. Executive Departure • Mar 15
Chief Financial Officer has left the company On the 12th of March, Gary Sender's tenure as Chief Financial Officer ended after 3.9 years in the role. As of December 2020, Gary personally held only 20.54k shares (US$50k worth at the time). Gary is the only executive to leave the company over the last 12 months. Reported Earnings • Mar 13
Full year 2020 earnings released: US$5.41 loss per share (vs US$11.15 loss in FY 2019) The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: US$5.03m (down 47% from FY 2019). Net loss: US$69.5m (loss narrowed 16% from FY 2019). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 69% per year, which means it is significantly lagging earnings. Analyst Estimate Surprise Post Earnings • Mar 13
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 22%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Over the next year, revenue is forecast to grow 87%, compared to a 22% growth forecast for the Pharmaceuticals industry in the US. Is New 90 Day High Low • Mar 02
New 90-day low: US$1.92 The company is down 56% from its price of US$4.40 on 01 December 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Is New 90 Day High Low • Dec 10
New 90-day low: US$3.40 The company is down 42% from its price of US$5.83 on 10 September 2020. The American market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Reported Earnings • Nov 08
Third quarter 2020 earnings released: US$0.09 loss per share Third quarter 2020 results: Net loss: US$13.0m (loss narrowed 27% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings. Analyst Estimate Surprise Post Earnings • Nov 08
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 187%. Earnings per share (EPS) also surpassed analyst estimates by 5.9%. Over the next year, revenue is forecast to grow 423%, compared to a 30% growth forecast for the Pharmaceuticals industry in the US. Major Estimate Revision • Nov 03
Analysts update estimates The 2020 consensus revenue estimate was lowered from US$5.58m to US$3.58m. Earning per share (EPS) estimate was unchanged from the last update at -US$0.48. The Pharmaceuticals industry in the US is expected to see an average net income growth of 6.7% next year. The consensus price target of US$1.75 was unchanged from the last update. Share price is down by 8.3% to US$0.49 over the past week. Is New 90 Day High Low • Oct 29
New 90-day low: US$0.51 The company is down 33% from its price of US$0.76 on 31 July 2020. The American market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Sep 25
New 90-day low: US$0.53 The company is down 24% from its price of US$0.70 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.